Zum Hauptinhalt springen Zur Suche springen Zur Hauptnavigation springen
Beschreibung
Phase I trials are a critical first step in the study of novel cancer therapeutic approaches. Their primary goals are to identify the recommended dose, schedule and pharmacologic behavior of new agents or new combinations of agents and to describe the adverse effects of treatment. In cancer therapeutics, such studies have particular challenges. Due to the nature of the effects of treatment, most such studies are conducted in patients with advanced malignancy, rather than in healthy volunteers. Further, the endpoints of these trials are usually measures adverse effects rather than molecular target or anti-tumor effects. These factors render the design, conduct, analysis and ethical aspects of phase I cancer trials unique. As the only comprehensive book on this topic, Phase I Cancer Clinical Trials is a useful resource for oncology trainees or specialists interested in understanding cancer drug development. New to this edition are chapters on Phase 0 Trials and Immunotherapeutics, and updated information on the process, pitfalls, and logistics of Phase I Trials
Phase I trials are a critical first step in the study of novel cancer therapeutic approaches. Their primary goals are to identify the recommended dose, schedule and pharmacologic behavior of new agents or new combinations of agents and to describe the adverse effects of treatment. In cancer therapeutics, such studies have particular challenges. Due to the nature of the effects of treatment, most such studies are conducted in patients with advanced malignancy, rather than in healthy volunteers. Further, the endpoints of these trials are usually measures adverse effects rather than molecular target or anti-tumor effects. These factors render the design, conduct, analysis and ethical aspects of phase I cancer trials unique. As the only comprehensive book on this topic, Phase I Cancer Clinical Trials is a useful resource for oncology trainees or specialists interested in understanding cancer drug development. New to this edition are chapters on Phase 0 Trials and Immunotherapeutics, and updated information on the process, pitfalls, and logistics of Phase I Trials
Über den Autor
EAE: Head, Department of Oncology, Queen's University, Medical Director, Oncology Program, Kingston General Hospital, Cancer Centre of Southeastern Ontario, Kingston, Canada; CT: Professor of Clinical Pharmacology and Oncology, Head, Section of Clinical Cancer Research Groups, Leeds Institute of Cancer Studies and Pathology, St. James's Institute of Oncology Leeds, UK; MB: Founder and Chairman, International Drug Development Institute, Louvain-la-Neuve, Belgium, Associate Professor of Biostatistics, Universiteit Hasselt Diepenbeek, Belgium
Inhaltsverzeichnis
  • 1. Introduction

  • 2. Preclinical Data and Requirements

  • 3. Phase 0 Clinical Trials

  • 4. Basics of Phase I Design: First-in-man Studies

  • 5. Ethical Issues in First-in-human Phase I Cancer Trials

  • 6. Phase I Trials in Special Populations and Circumstances

  • 7. Phase I Trials of Immunotherapeutics

  • 8. Statistical Designs for First-in-human Phase I Trials

  • 9. Writing the Protocol

  • 10. Practical Aspects of Pharmacokinetics and Pharmacodynamics

  • 11. Process, Pitfalls, and Logistics of Phase I Trials

  • 12. Reporting and Interpreting Results

  • Appendix: Useful Web Resources

Details
Erscheinungsjahr: 2015
Fachbereich: Andere Fachgebiete
Genre: Importe, Medizin
Rubrik: Wissenschaften
Medium: Taschenbuch
Inhalt: Kartoniert / Broschiert
ISBN-13: 9780199359011
ISBN-10: 0199359016
Sprache: Englisch
Einband: Kartoniert / Broschiert
Redaktion: Eisenhauer, Elizabeth A
Twelves, Christopher
Buyse, Marc
Hersteller: Oxford University Press
Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, D-36244 Bad Hersfeld, gpsr@libri.de
Maße: 234 x 156 x 20 mm
Von/Mit: Elizabeth A Eisenhauer (u. a.)
Erscheinungsdatum: 07.05.2015
Gewicht: 0,562 kg
Artikel-ID: 120664899

Ähnliche Produkte